Overview
Lydia Horndler practices practicing medicine in Madrid, Spain.
Her clinical expertise encompasses Severe Acute Respiratory Syndrome (SARS) and Triple-Negative Breast Cancer.
She is actively involved in clinical research, co-authoring 9 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Lydia Horndler
Is Lydia Horndler a top-rated expert for Severe Acute Respiratory Syndrome (SARS)?
MediFind is an objective health platform that identifies experts based on real-world data. Lydia Horndler is classified as an Experienced expert for Severe Acute Respiratory Syndrome (SARS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Lydia Horndler participate in research or clinical trials?
Yes. Lydia Horndler has published 9 articles and abstracts on conditions like Severe Acute Respiratory Syndrome (SARS). You can view a list of Lydia Horndler's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Severe Acute Respiratory Syndrome (SARS)Ms. Horndler isExperienced. Learn about Severe Acute Respiratory Syndrome (SARS).
- Triple-Negative Breast CancerMs. Horndler isExperienced. Learn about Triple-Negative Breast Cancer.